Jonathan Wolleben
Stock Analyst at Citizens
(4.58)
# 215
Out of 5,090 analysts
231
Total ratings
54.62%
Success rate
23.09%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $6.39 | +447.73% | 9 | Nov 14, 2025 | |
| SVRA Savara | Maintains: Market Outperform | $11 → $10 | $6.50 | +53.85% | 10 | Nov 13, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $254 → $259 | $79.99 | +223.79% | 9 | Nov 11, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $16.43 | +70.42% | 6 | Nov 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $69 → $102 | $89.65 | +13.78% | 13 | Nov 7, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $143 → $108 | $46.66 | +131.49% | 17 | Nov 7, 2025 | |
| ALT Altimmune | Maintains: Market Outperform | $15 → $14 | $5.24 | +167.18% | 14 | Nov 7, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Market Outperform | $27 → $25 | $7.59 | +229.38% | 10 | Nov 5, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $485 → $527 | $577.30 | -8.71% | 14 | Nov 5, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $81 → $95 | $68.48 | +38.73% | 12 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $5.89 | +239.85% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.93 | - | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $12.58 | +130.52% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $135 → $142 | $104.60 | +35.76% | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.70 | +386.49% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $26.42 | +96.82% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $8 | $4.01 | +99.50% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $89 → $87 | $34.56 | +151.74% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.09 | +282.78% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $13.90 | +51.08% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $1.20 | +1,150.00% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.43 | +195.49% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $31.97 | +18.86% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $42.36 | +18.04% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $68.01 | +32.33% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $124.32 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $564.93 | -14.15% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.66 | +1,108.82% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $28.61 | -16.10% | 1 | May 12, 2023 |
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $6.39
Upside: +447.73%
Savara
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $6.50
Upside: +53.85%
Spruce Biosciences
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $79.99
Upside: +223.79%
KalVista Pharmaceuticals
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $16.43
Upside: +70.42%
Protagonist Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $69 → $102
Current: $89.65
Upside: +13.78%
Crinetics Pharmaceuticals
Nov 7, 2025
Maintains: Market Outperform
Price Target: $143 → $108
Current: $46.66
Upside: +131.49%
Altimmune
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $5.24
Upside: +167.18%
BioCryst Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $7.59
Upside: +229.38%
Madrigal Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $485 → $527
Current: $577.30
Upside: -8.71%
Mirum Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $81 → $95
Current: $68.48
Upside: +38.73%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $5.89
Upside: +239.85%
Oct 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $12.93
Upside: -
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $12.58
Upside: +130.52%
Sep 25, 2025
Maintains: Market Outperform
Price Target: $135 → $142
Current: $104.60
Upside: +35.76%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.70
Upside: +386.49%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $26.42
Upside: +96.82%
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $4.01
Upside: +99.50%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $34.56
Upside: +151.74%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.09
Upside: +282.78%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $13.90
Upside: +51.08%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.20
Upside: +1,150.00%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.43
Upside: +195.49%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $31.97
Upside: +18.86%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $42.36
Upside: +18.04%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $68.01
Upside: +32.33%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $124.32
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $564.93
Upside: -14.15%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.66
Upside: +1,108.82%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $28.61
Upside: -16.10%